BRAF and neoplasm: Among these, the BRAF inhibitors—vemurafenib (Zelboraf), dabrafenib (Tafinlar), and encorafenib (Braftovi)—have shown remarkable efficacy in patients harboring BRAF V600E/K mutations, producing rapid tumor regression and high initial response rates [12,13,14].